{"transactions":[{"id":4631452,"issuer":{"id":7810,"kind":"organization","name":"Greenland Mines Ltd","symbol":"GRML"},"owners":[{"id":35202,"kind":"person","name":"El-Dada Riad Hussein","position":1,"cik":"0001926018","reported_name":"El-Dada Riad Hussein","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Common Stock","published_at":"2026-10-06T00:18:47.000Z","date":"2026-10-01","kind":"sale","planned":false,"acquired":false,"shares":3500,"price":9.3506,"value":32727.1,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-26-106940","document":"marketforms-74106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1926018/000121390026106940/marketforms-74106.xml","form_type":"4"}},{"id":725662,"issuer":{"id":7810,"kind":"organization","name":"Greenland Mines Ltd","symbol":"GRML"},"owners":[{"id":35202,"kind":"person","name":"El-Dada Riad Hussein","position":1,"cik":"0001926018","reported_name":"El-Dada Riad Hussein","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T20:30:14.000Z","date":"2026-06-25","kind":"sale","planned":false,"acquired":false,"shares":175000,"price":0.2317,"value":40547.5,"ownership":{"direct":true},"balance_after":175000,"source":{"system":"sec-edgar","filing":"0001213900-26-072646","document":"marketforms-73471.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1926018/000121390026072646/marketforms-73471.xml","form_type":"4"}},{"id":856154,"issuer":{"id":7810,"kind":"organization","name":"Greenland Mines Ltd","symbol":"GRML"},"owners":[{"id":35202,"kind":"person","name":"El-Dada Riad Hussein","position":1,"cik":"0001926018","reported_name":"El-Dada Riad Hussein","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-06T21:02:24.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":350000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting person received the shares as a grant under the company's Equity Incentive Plan."}],"balance_after":350000,"source":{"system":"sec-edgar","filing":"0001213900-26-024627","document":"marketforms-72439.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1926018/000121390026024627/marketforms-72439.xml","form_type":"4"}},{"id":974680,"issuer":{"id":7810,"kind":"organization","name":"Greenland Mines Ltd","symbol":"GRML"},"owners":[{"id":35202,"kind":"person","name":"El-Dada Riad Hussein","position":1,"cik":"0001926018","reported_name":"El-Dada Riad Hussein","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2025-12-10T18:38:05.000Z","date":"2025-12-10","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0.41,"value":8200.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options are fully vested and can be exercised at any time."}],"balance_after":60000,"derivative":{"exercise_price":0.41,"expiration_date":"2035-01-16","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001213900-25-119993","document":"marketforms-71508.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1926018/000121390025119993/marketforms-71508.xml","form_type":"4"}},{"id":1071491,"issuer":{"id":7810,"kind":"organization","name":"Greenland Mines Ltd","symbol":"GRML"},"owners":[{"id":35202,"kind":"person","name":"El-Dada Riad Hussein","position":1,"cik":"0001926018","reported_name":"El-Dada Riad Hussein","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2025-08-08T10:00:20.000Z","date":"2025-08-07","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0.41,"value":4100.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options are fully vested and can be exercised at any time."}],"balance_after":40000,"derivative":{"exercise_price":0.41,"expiration_date":"2035-01-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001213900-25-073274","document":"marketforms-70267.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1926018/000121390025073274/marketforms-70267.xml","form_type":"4"}},{"id":1739382,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":35202,"kind":"person","name":"El-Dada Riad Hussein","position":1,"cik":"0001926018","reported_name":"El-Dada Riad Hussein","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-11-16T21:12:42.000Z","date":"2023-11-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23122,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 28, 2023, Mallinckrodt plc (the \"Company\") and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On September 20, 2023, the Company's directors presented a petition before the High Court of Ireland (the \"Irish High Court\") seeking the appointment of an examiner (the \"Examiner\") to the Company, thereby commencing examinership proceedings with respect to the Company in Ireland."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On October 10, 2023, the Bankruptcy Court entered an order confirming the First Amended Prepackaged Joint Chapter 11 Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates (as may be amended or supplemented from time to time in accordance with its terms, the \"Plan\"). On November 10, 2023, the Irish High Court made an order confirming a scheme of arrangement proposed by the Examiner that is based on and consistent in all respects with the Plan (the \"Scheme\"). On November 14, 2023 (the \"Effective Date\"), the Plan and the Scheme became effective and the Company emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of the Company's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such Ordinary Shares, were cancelled and extinguished pursuant to the Plan and the Scheme. In connection with emergence, the reporting person ceased to be a Section 16 reporting person. This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-119110","document":"tm2330745-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1926018/000110465923119110/tm2330745-4_4seq1.xml","form_type":"4"}},{"id":1842131,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":35202,"kind":"person","name":"El-Dada Riad Hussein","position":1,"cik":"0001926018","reported_name":"El-Dada Riad Hussein","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-06-29T22:51:57.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26277,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (the \"RSUs\") granted to the reporting person on January 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc (\"Mallinckrodt\") in connection with the Board of Directors (the \"Board\") of Mallinckrodt's approval of changes to the compensation of non-employee members of the Board (such changes, the \"Compensation Changes\"). In connection with the Compensation Changes, and in consideration of the cancelation of the RSUs, the reporting person will receive (i) in the event of a bankruptcy filing, additional cash compensation for 2023 of $210,000 or (ii) in the absence of a bankruptcy filing, additional cash compensation for 2023 of $245,000. In either event, the amounts are to be prepaid pro rata on a quarterly basis and paid in arrears for the prior quarters of fiscal year 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units (the \"RSUs\") granted to the reporting person on January 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc (\"Mallinckrodt\") in connection with the Board of Directors (the \"Board\") of Mallinckrodt's approval of changes to the compensation of non-employee members of the Board (such changes, the \"Compensation Changes\"). In connection with the Compensation Changes, and in consideration of the cancelation of the RSUs, the reporting person will receive (i) in the event of a bankruptcy filing, additional cash compensation for 2023 of $210,000 or (ii) in the absence of a bankruptcy filing, additional cash compensation for 2023 of $245,000. In either event, the amounts are to be prepaid pro rata on a quarterly basis and paid in arrears for the prior quarters of fiscal year 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The restricted stock units (the \"RSUs\") granted to the reporting person on January 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc (\"Mallinckrodt\") in connection with the Board of Directors (the \"Board\") of Mallinckrodt's approval of changes to the compensation of non-employee members of the Board (such changes, the \"Compensation Changes\"). In connection with the Compensation Changes, and in consideration of the cancelation of the RSUs, the reporting person will receive (i) in the event of a bankruptcy filing, additional cash compensation for 2023 of $210,000 or (ii) in the absence of a bankruptcy filing, additional cash compensation for 2023 of $245,000. In either event, the amounts are to be prepaid pro rata on a quarterly basis and paid in arrears for the prior quarters of fiscal year 2023."}],"balance_after":23122,"source":{"system":"sec-edgar","filing":"0001104659-23-076468","document":"tm2320181-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1926018/000110465923076468/tm2320181-2_4seq1.xml","form_type":"4"}},{"id":1842130,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":35202,"kind":"person","name":"El-Dada Riad Hussein","position":1,"cik":"0001926018","reported_name":"El-Dada Riad Hussein","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-06-29T22:51:57.000Z","date":"2023-06-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":3154,"price":1.28,"value":4037.12,"ownership":{"direct":true},"balance_after":49399,"source":{"system":"sec-edgar","filing":"0001104659-23-076468","document":"tm2320181-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1926018/000110465923076468/tm2320181-2_4seq1.xml","form_type":"4"}},{"id":2063196,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":35202,"kind":"person","name":"El-Dada Riad Hussein","position":1,"cik":"0001926018","reported_name":"El-Dada Riad Hussein","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-01-05T23:00:55.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":26277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported ordinary shares represent restricted stock units (\"RSUs\"), which will be settled in an equal number of MNK ordinary shares and will vest ratably on each of the first two anniversaries of MNK's emergence from Chapter 11 proceedings on June 16, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 26,277 newly awarded RSUs and 26,276 RSUs previously reported in Table II."}],"balance_after":52553,"source":{"system":"sec-edgar","filing":"0001104659-23-001540","document":"tm231710-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1926018/000110465923001540/tm231710-2_4seq1.xml","form_type":"4"}},{"id":2159509,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":35202,"kind":"person","name":"El-Dada Riad Hussein","position":1,"cik":"0001926018","reported_name":"El-Dada Riad Hussein","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-09-15T01:15:20.000Z","date":"2022-08-16","kind":"disposition_to_issuer","acquired":false,"shares":22533,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"(1) As previously disclosed, on August 16, 2022, Riad H. El-Dada agreed to relinquish 22,533 of the restricted stock units (\"RSUs\") which were previously granted to him on July 1, 2022, with relinquishment to be applied ratably across both vesting tranches of such award, to remedy ministerial errors in computation and to correct for the fact that the RSU grant may have as a technical matter exceeded the applicable annual grant maximum amount set forth in the Mallinckrodt Pharmaceuticals 2022 Stock and Incentive Plan (the \"MIP\"). Mallinckrodt plc (\"Mallinckrodt\") has agreed that, as soon as reasonably practical following January 1, 2023, Mallinckrodt will grant to Mr. El-Dada 26,277 RSUs, subject to his continued service through such date and the MIP grant value limit, which will vest ratably on each of the first two anniversaries of emergence."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"(1) As previously disclosed, on August 16, 2022, Riad H. El-Dada agreed to relinquish 22,533 of the restricted stock units (\"RSUs\") which were previously granted to him on July 1, 2022, with relinquishment to be applied ratably across both vesting tranches of such award, to remedy ministerial errors in computation and to correct for the fact that the RSU grant may have as a technical matter exceeded the applicable annual grant maximum amount set forth in the Mallinckrodt Pharmaceuticals 2022 Stock and Incentive Plan (the \"MIP\"). Mallinckrodt plc (\"Mallinckrodt\") has agreed that, as soon as reasonably practical following January 1, 2023, Mallinckrodt will grant to Mr. El-Dada 26,277 RSUs, subject to his continued service through such date and the MIP grant value limit, which will vest ratably on each of the first two anniversaries of emergence."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"(1) As previously disclosed, on August 16, 2022, Riad H. El-Dada agreed to relinquish 22,533 of the restricted stock units (\"RSUs\") which were previously granted to him on July 1, 2022, with relinquishment to be applied ratably across both vesting tranches of such award, to remedy ministerial errors in computation and to correct for the fact that the RSU grant may have as a technical matter exceeded the applicable annual grant maximum amount set forth in the Mallinckrodt Pharmaceuticals 2022 Stock and Incentive Plan (the \"MIP\"). Mallinckrodt plc (\"Mallinckrodt\") has agreed that, as soon as reasonably practical following January 1, 2023, Mallinckrodt will grant to Mr. El-Dada 26,277 RSUs, subject to his continued service through such date and the MIP grant value limit, which will vest ratably on each of the first two anniversaries of emergence."}],"balance_after":26276,"derivative":{"underlying":"Ordinary Shares","underlying_shares":22533},"source":{"system":"sec-edgar","filing":"0001104659-22-100150","document":"tm2225913-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1926018/000110465922100150/tm2225913-3_4seq1.xml","form_type":"4"}},{"id":2212341,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":35202,"kind":"person","name":"El-Dada Riad Hussein","position":1,"cik":"0001926018","reported_name":"El-Dada Riad Hussein","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-07-07T01:11:10.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":48809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The grant of restricted stock units vests in equal installments on each of the first and second anniversaries of the date of Mallinckrodt plc's emergence from bankruptcy (June 16, 2022). Each restricted stock unit represents one Ordinary Share, and may be redeemed in either cash or stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant of restricted stock units vests in equal installments on each of the first and second anniversaries of the date of Mallinckrodt plc's emergence from bankruptcy (June 16, 2022). Each restricted stock unit represents one Ordinary Share, and may be redeemed in either cash or stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The grant of restricted stock units vests in equal installments on each of the first and second anniversaries of the date of Mallinckrodt plc's emergence from bankruptcy (June 16, 2022). Each restricted stock unit represents one Ordinary Share, and may be redeemed in either cash or stock."}],"balance_after":48809,"derivative":{"underlying":"Ordinary Shares","underlying_shares":48809},"source":{"system":"sec-edgar","filing":"0000899243-22-025535","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1926018/000089924322025535/doc4.xml","form_type":"4"}}]}